An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Personalis, Inc. (NASDAQ: PSNL), a leader in advanced cancer genomics, announced its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 2:00 p.m. Eastern Time. The event will be accessible via a webcast link for attendees. Personalis is known for its Personalis NeXT Platform®, which provides comprehensive genomic information from tissue samples, facilitating precision cancer therapies and diagnostics. The lab is CLIA certified and CAP accredited, ensuring clinical accuracy and efficiency.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time.
The webcast link is available only for those who are attending the BTIG conference.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. To enable cancer sequencing, the PersonalisClinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
When is the Personalis presentation at the BTIG conference?
Personalis, Inc. will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 2:00 p.m. Eastern Time.
What is the main focus of Personalis, Inc.?
Personalis, Inc. specializes in advanced cancer genomics, enabling next-generation precision therapies and diagnostics.
Where can I find the Personalis webcast link for the conference?
The webcast link for the Personalis presentation is available only to those attending the BTIG conference.
What certification does the Personalis clinical laboratory have?
The Personalis clinical laboratory is CLIA certified and CAP accredited.
What does the Personalis NeXT Platform® offer?
The Personalis NeXT Platform® provides genomic information on approximately 20,000 human genes and immune system data from a single tissue sample.
